Guest Editorial: Sheila Fallon Friedlander, MD
Why Are We So Afraid of the Littlest Ones? Why do we all get so anxious when we receive such a call? I am triple boarded (pediatrics, dermatology, pediatric dermatology), but I still shudder when the NICU calls. There are several reasons why we are so anxious. First, we know a baby’s skin, particularly associated with […]
Updates in Diagnosing and Treating Idiopathic Pruritus
Dr. Tejesh Patel discusses what’s new and emerging in the diagnosis and treatment of idiopathic pruritus, including screening tips, physical finding insights, and on- and off-label medication use. Tejesh Patel, MD, Professor and Chair of Dermatology at University of Tennessee Health Science Center, Memphis, Tennessee “Historically, patients with idiopathic pruritus have been challenging to treat. […]
FDA Approves First Drug Specifically for Generalized Pustular Psoriasis
Dr. Ted Rosen details FDA-approved spesolimab as the first drug specifically indicated for the treatment of generalized pustular psoriasis flares in adults. Ted Rosen, MD, FAAD Editor-in-Chief Spesolimab (Spevigo, Boehringer Ingelheim Pharmaceuticals) is a humanized monoclonal IgG1 antibody directed against interleukin-36 (IL-36) signaling. This agent binds to IL-36R, thereby preventing activation of this receptor by ligands. […]
THE DERMATOLOGY DIGEST | VOL. 3, NO. 8
The Making of ‘Thought Leader AI’
From inspiration to launch, Thought Leader AI, ParaPro’s medical education platform, was developed to raise awareness and educate practitioners efficiently, with the potential to eradicate a widespread public health issue. “Two and a half years ago, the Shoah Foundation was highlighted on 60 Minutes. ICT’s [University of Southern California Institute for Creative Technologies’] technology allowed people to experience an interactive conversation with Holocaust survivors, […]
JAK Inhibitors for Alopecia Areata
Dr. Antonella Tosti discusses the FDA’s first drug treatment approved for alopecia areata, JAK inhibitor baricitinib, as well as two JAK inhibitors that have filed with the FDA for the indication. Antonella Tosti, MD, Fredric Brandt Endowed Professor of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida “This year has […]
Seborrheic Dermatitis: Unmet Needs and Innovations
Seborrheic dermatitis is a common inflammatory skin disease with underappreciated impacts on patient quality of life. In part 2 of this educational series on innovations in topical treatments for inflammatory skin disorders, Dr. Raj Chovatiya discusses the pathophysiology, clinical presentation, and limitations of current therapies for treating seborrheic dermatitis. About this Series This 3-part educational […]
Atopic Dermatitis and Venous Thromboembolism Risk
Dr. Michael Ardern-Jones discusses a large study that suggests venous thromboembolism risk is significantly higher among those with atopic dermatitis and how this finding might impact care. Michael Ardern-Jones, BSc, MBBS, MRCP, DPhil, FRCP, Professor of Dermatology, University of Southampton, Southampton, United Kingdom “It has been known for quite a long time that people with […]
Do Antioxidants Offer UV Protection?
Dr. Henry Lim discusses the benefits of antioxidants in sunscreens, including recent research on their biologic properties and role in photoprotection. Henry Lim, MD, former chair, Department of Dermatology, Henry Ford Health, Detroit, Michigan “About 10 years ago, there was a study by Steven Wang1 to look at sunscreens that were then available that contained antioxidants. […]
Differentiating Longitudinal Melanonychia Etiologies in Skin of Color Patients
Dr. Shari Lipner discusses longitudinal melanonychia in skin of color patients and how to potentially differentiate nonmelanocytic from melanocytic causes. Shari R. Lipner, MD, PhD, Associate Professor of Clinical Dermatology and Director of the Nail Unit, Weill Cornell Medicine, New York, New York “Longitudinal melanonychia is very common in patients with skin of color. The […]